Sign in
Taking peoplePhase 2

Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial

Key facts

Who runs it
Stichting Radboud universitair medisch centrum
Where
Netherlands3 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
28 Oct 2024
Planned end
30 Sept 2025
Type of study
Interventional
Record updated
28 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Supratentorial non-traumatic ICH confirmed by CT, without a confirmed causative lesion on admission CT-angiography (e.g. aneurysm, AVM, DAVF, cerebral venous sinus thrombosis) or other known underlying lesion (e.g. tumour, cavernoma)
  • Minimal intracerebral haemorrhage volume of 10 mL
  • Intervention can be started within 8 hours from symptoms onset
  • Patient's or legal representative's informed consent

Who cannot take part

  • Known prior allergic reaction to gadolinium contrast or one of the constituents of its solution for administration
  • Live vaccinations within the last 10 days prior to this ICH
  • Use of immunosuppressive or immune-modulating therapy at admission
  • Known allergy to anakinra or other products that are produced by DNA technology using the micro-organism E. coli
  • Known active malignancy
  • Severe infection at admission, requiring antibiotic treatment
  • Known active tuberculosis or active hepatitis
  • Pre-stroke modified Rankin Scale score ≥ 3
  • Severe renal impairment (eGFR <30ml/min/1.73m)
  • Neutropenia (Absolute Neutrophil Count (ANC) <1.5 x 109/L )
  • Severe ICH, unlikely to survive the first 72 hours (defined as Glasgow Coma Scale score < 6 at time of consent)
  • Standard contraindications to MRI
  • Confirmed or suspected haemorrhagic transformation of an arterial or venous infarct
  • Planned neurosurgical haematoma evacuation
  • Pregnancy or breast-feeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the effect of high-dose versus low-dose anakinra compared to standard medical management on cerebral oedema development after spontaneous supratentorial intracerebral haemorrhage.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
28 October 2024